Bivalirudin in Peripheral Vascular Interventions
all geographic regions within the United States over a broad range of healthcare facility sizes and architectures (ie, academic and nonacademic hospitals), located in both urban and rural settings. 7, 8 More than 5 million inpatient discharges and 35 million outpatient visits are recorded annually. The database records standard data elements available in most hospital discharge files, such as demographic data, diagnoses, and procedures performed (International Classification of Diseases Ninth Revision, clinical modification [ICD-9-CM] diagnosis and procedural codes), and discharge destination. The database also contains patient-level, day of service billed items, including medications, laboratory, diagnostic, and therapeutic services delivered to the patient during hospitalization. The Premier database has contributed multiple peer-reviewed publications in a wide spectrum of disease states, and it has supported outcomes research conducted by government agencies. 9 The Premier Research Database is publically available and is deidentified, so that it is impossible to link a record to a particular individual, which is in accordance with the 1996 Health Insurance Portability and Accountability Act. 10, 11 Therefore, our analysis using this database does not constitute human subject research and is not subject to International Review Board approval.
Study Population
Adults (age, ≥18 years) who were admitted with a primary diagnosis of atherosclerosis of native arteries of the extremities (ICD-9-CM diagnosis codes of 440. between January 2008 and December 2012 and underwent a PVI procedure with or without stenting (ICD-9-CM procedural codes of 00.55 [insertion of drug-eluting stent of other peripheral vessel], 00.60 [insertion of drug-eluting stent of superficial femoral artery], 39.50 [angioplasty of other noncoronary vessel], and 39.90 [insertion of non-drug-eluting stent peripheral vessel stent]) were included. Patients undergoing PVI on target vessels above the origin of the iliac arteries were excluded from the analysis. We considered as outliers for extreme cases with length of hospital stay >90 days and total hospital cost >$1 million dollars and excluded them from the analysis (Figure 1 ).
Baseline and Procedural Characteristics
Baseline characteristics, including demographics and insurance status, were captured from the database. Patient comorbidities were derived from secondary ICD-9-CM diagnosis codes (Appendix I in the Data Supplement). Concomitant medications were captured at 2 time points; first, as the day before or the day of PVI and second, at the day post PVI as determined by billing charges. Hospital characteristics (size, teaching status, region, and urban/rural) were captured from the database. Symptoms for PVI were determined based on primary ICD-9-CM codes of 440.21 (intermittent claudication), 440.22 (rest pain), 440.23 (ulceration), 440.24 (gangrene), and 440.20 (unspecified). For the purposes of this analysis, we grouped rest pain, ulceration, and gangrene as 1 symptom category: critical limb ischemia. Procedural information, including type of endovascular procedure, stent type, number of stents used, and number of target vessels treated was derived from ICD-9-CM procedural codes (Appendix I in the Data Supplement). Specialty of the PVI operator (cardiology versus noncardiology [ie, radiology and vascular surgery]) was captured from the database.
Exposure
Anticoagulant choice was determined through charges from hospital billing data. Patients were categorized into 1 of 2 groups (bivalirudin or UFH) based on the anticoagulant used on the day of the PVI procedure. Patients were excluded from analyses if there were no charges for any anticoagulant, if there were charges for a GPI or for lowmolecular weight heparin.
Outcomes
There were 5 prespecified individual clinical outcomes and 2 composite clinical outcomes included in this analysis. Individual in-hospital outcomes included (1) mortality defined as discharge status of death; (2) myocardial infarction defined based on ICD-9-CM codes (997.1x and 410.xx) for myocardial infarction complications after admission; (3) stroke, including transient ischemic attack, based on ICD-9-CM codes (997.0x, 430.xx, 431.xx, 432.9, 433.x1, 434.x1, 435.9, and 436); (4) lower extremity amputation defined occurring on or after the day of PVI based on ICD-9-CM procedural codes (84.1x); and (5) transfusion defined as ≥1 unit whole blood, packed red blood cells, fresh frozen plasma, or platelets occurring on or after the day of PVI of as determined by charges appearing on billing records. Prespecified composite end points included major adverse cardiovascular events (MACEs) defined as death, myocardial infarction, stroke, or amputation during hospitalization and net adverse clinical events (NACEs) defined as death, myocardial infarction, stroke, amputation, or transfusion during hospitalization.
Statistical Analysis
Discrete variables were summarized as frequencies and percentages. Continuous variables were summarized as means with SDs. Unadjusted outcomes were presented as percentages, odds ratios and 95% confidence intervals and compared using χ 2 testing between the 2 treatment groups.
Because of the nonrandomized nature of this comparative analysis, we used propensity score matching (PSM) to minimize the impact of baseline imbalances and selection bias. First, a nonparsimonious list of variables that existed before study medication administration was generated. These included patient demographic factors, insurance status, hospital characteristics, comorbidities, previous medication usage, and physician specialty. A PS, the log-odds (logit) of the probability that a patient received bivalirudin, was modeled as a function of these variables using multivariate logistic regression. A 1-to-1 match without replacement was performed on the basis of the estimated PS for each patient. 12 Bivalirudin patients were randomly selected and each was then matched to the closest UFH patient. Only UFH patients who had an estimated PS within 0.6 SD of the selected bivalirudin patient were eligible for matching. 13 If there was no UFH patient within the caliper, this specific bivalirudin patient was
WHAT IS KNOWN
• Peripheral arterial disease is a prevalent syndrome, afflicting ≈7 million individuals in the United States.
• When compared with medical therapy, peripheral vascular interventions improve health-related quality of life.
• There exist no randomized or large studies comparing the relative efficacy and safety of unfractionated heparin and bivalirudin in patients undergoing peripheral vascular interventions.
WHAT THE STUDY ADDS
• This analysis suggests that in patients undergoing peripheral vascular interventions, when compared with unfractionated heparin, adjunctive therapy with bivalirudin is associated with significant reductions in mortality, bleeding and the composite outcomes of major adverse cardiac events (death, myocardial infarction, stroke, or amputation) and net adverse clinical events (death, myocardial infarction, stroke, amputation, or transfusion).
• Bivalirudin-associated reductions in important clinical end points are consistent across all clinically relevant patient subgroups. Bivalirudin in Peripheral Vascular Interventions removed and the next was selected for matching. Recognizing the significant effect of disease symptoms and treating physician's specialty on outcomes, we stratified all patients based on their presenting symptoms (claudication, rest pain, ulceration, or gangrene) and by operating physician specialty (cardiologist versus noncardiologist) and matched a bivalirudin patient with an UFH patient only if both patients had the same symptom category, and they were treated by an operator with the same specialty.
We assessed the success of PSM by examining standardized differences in the variables between the matched bivalirudin and the UFH groups. It has been suggested that a standardized difference >10% represents the threshold for an important imbalance in a given confounder between treatment groups. 14, 15 If the standardized difference was >10%, we re-estimated the variables in the logistic regression model and repeated this process until all standardized differences were <10%. After PSM was completed, conditional logistic regression was performed on the matched sets to compare each outcome between the 2 anticoagulant strategies. Subgroup analyses were performed on prespecified, clinically relevant patient subpopulations to test for consistency of the observed association.
The α level of significance was set to 0.05. All P values being presented were 2-sided. No adjustment was made for multiple comparisons given that this was an exploratory analysis. All analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, NC).
Sensitivity Analyses
Two sensitivity analyses were undertaken. First, a confirmatory logistic regression analysis was conducted on the entire study population to confirm the results obtained in the PSM-derived subpopulation. Second, we repeated the PSM analysis by including patients who also received GPI on the day of PVI. Because we did not know the indication for GPI (more likely for a bailout indication than elective), exclusion of these patients may have systematically excluded sicker patients from both treatment groups.
Results

Study Population
Between January 2008 and December 2012, there were 33 558 admissions identified with the qualifying principal diagnosis of a PVI procedure and an appropriate medicare severity diagnosis-related group. There were 9624 patients excluded from analysis for the following reasons: 266 had aortic or renal artery disease, 8052 had no record of an anticoagulant, 581 had low-molecular weight heparin administered, 648 received GPI in addition to UFH (n=454) or bivalirudin (n=194), 74 were documented as having received GPI only, 2 patients were missing a gender assignment, and 1 patient had a hospital stay of 146 days. The final population analyzed consisted of 23 934 patients from 357 hospitals; 4370 received bivalirudin and 19 564 received UFH (Figure 1 ).
Patient Characteristics
Baseline characteristics, comorbidities, and concomitant medications in both the overall and the PSM populations according to anticoagulant used are presented in Table 1 . In the overall population, there were notable differences between the 2 groups. Specifically, bivalirudin-treated patients were older, more often male, less frequently white, and they were more likely to be treated in an urban, nonteaching hospital setting. Bivalirudin patients also had more hypertension, diabetes mellitus, obesity, hyperlipidemia, stroke, coronary artery disease, previous PCI or coronary artery bypass graft surgery, and previous smoking. However, UFH patients more frequently had anemia, chronic obstructive pulmonary disease, congestive heart failure, and were current smokers. UFH patients were more likely to present with critical limb ischemia (50.1% versus 32.2%) and less likely to be treated by cardiologists (25.4% versus 87.8%). After PSM, baseline imbalances between groups were largely addressed (all standardized differences ≤10%), whereas the very large differences noted in the stratification variables of presenting symptom and operator specialty were completely eliminated. All values shown are percentages unless otherwise noted. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA, cardiovascular accident; PCI, percutaneous coronary intervention; PVI, percutaneous peripheral intervention; and PSM, propensity score matching; and UFH, unfractionated heparin.
*A patient might have multiple disease vessels and be counted in each vessel.
Bivalirudin in Peripheral Vascular Interventions Outcomes
Outcomes according to treatment group in the overall population (n=23 934) and PSM-matched population (n=7298) appear in Table 2 . Unadjusted outcomes were all significantly more favorable in bivalirudin-treated patients in the overall population. After PSM, bivalirudin treatment was associated with incidence rate reduction for all in-hospital outcomes. However, statistical significance was only present for mortality, transfusions, MACE, and NACE.
Subgroup Analyses
To assess for the consistency of association with bivalirudin, the end points of MACE and NACE were assessed across clinically relevant subgroups (age, gender, diabetes mellitus, congestive heart failure, anemia, presenting symptoms, atherectomy, target vessels, and stent implanted) in the PS-matched population. Each treatment-by-subgroup interaction P value was calculated by logistic regression with the independent variables being treatment (bivalirudin versus UFH), subgroup and the treatment-by-subgroup interaction. Bivalirudin demonstrated a consistent treatment effect in the subgroups examined in this analysis with an interaction only identified around the use of stents for MACE outcomes (interaction P=0.026; Figure 2A ) and a borderline interaction between presenting symptoms for NACE (interaction P=0.047; Figure 2B ), however, the treatment effect of bivalirudin in both cases remained in the same direction.
Sensitivity Analyses
Outcome data from multivariate logistic regression modeling, which in general confirmed the results obtained with PSM, appear in Table 3 . Bivalirudin treatment was associated with significant reductions in mortality, transfusion, MACE, and NACE. The odds of amputation with bivalirudin was lower with logistic regression that was noted with the PSM method (odds ratio, 0.65 versus odds ratio, 0.73; P=0.006 versus P=0.093). All amputations were minor toe amputations, there were no major amputations. The second sensitivity analysis (Table 4) used the PSM technique but included an additional 645 patients (454 UFH and 194 bivalirudin) who received GPI, assuming that these agents were administered as bailout therapy. This analysis similarly showed that bivalirudin treatment was associated with significant reductions in mortality, amputation, transfusion, MACE, and NACE.
Discussion
In this nationwide, multiyear PS-matched analysis using clinical and economic data, we found that in patients undergoing PVI, the use of bivalirudin was associated with significantly lower in-hospital mortality, fewer transfusions and lower MACE and NACE rates compared with UFH. The findings were consistent across a broad range of prespecified and clinically relevant subgroups. Evidence from randomized clinical trials supports the use of bivalirudin in patients undergoing PCI based on consistent observations of lower rates of bleeding, transfusions, and thrombocytopenia and improved overall net clinical outcomes. [4] [5] [6] Large database observational studies have confirmed these findings in real-world practice and have also demonstrated lower in-hospital mortality with bivalirudin compared with heparin-based regimens. 7, 16, 17 PVI has been recently documented to improve health-related quality of life 3 ; however, the optimal adjunctive anticoagulant strategy has not been defined. Because of the procedural similarities between PCI and PVI, many operators have adopted the use of UFH and bivalirudin as procedural anticoagulation based on their performance in the PCI arena. 18 Initial observational and single center studies have established the feasibility of bivalirudin in this setting and have suggested that clinical outcomes may be improved through reduction in bleeding. [19] [20] [21] [22] [23] [24] [25] In the absence of randomized data, our investigation represents the largest observational comparative analysis and proposes an association between bivalirudin and improved short-term outcomes after PVI. Evidence derived from comparative analyses in observational, nonrandomized data sets should always be interpreted with caution and only after robust statistical methods have been employed in an effort to account for baseline imbalances. This is a very important consideration, as large and even significant differences observed between treatments may be completely related to underlying confounders Before PSM is based on entire study population. The results were completely unadjusted. After PSM is based on the matched population for whom baseline characteristics were balanced through the PSM technique. CI indicates confidence interval; MACE, major adverse cardiac events; MI, myocardial infarction; NACE, net adverse clinical events; PSM, propensity score matching; and UFH, unfractionated heparin. and could disappear with appropriate statistical adjustment. In our analysis, there were important baseline differences noted between the bivalirudin and heparin-treated patients and accordingly we considered that PSM was an appropriate method for the primary comparison. In addition, we excluded all patients who were also treated with GPI in order to allow for a more unadulterated comparison between the 2 anticoagulants. The primary results of the current analysis are, therefore, derived from the comparison of PSM pairs of patients who did not receive GPI. The reductions in in-hospital mortality, transfusions, MACE and NACE were consistently observed among the overall population and the PSM population, including clinically relevant subgroups, and were also present in the 2 additional sensitivity analyses that included a logistic regression-adjusted comparison in the overall population and a comparison in the PSM population that included GPI-treated patients. The odds ratio close to 1 for MACE in patients receiving stents might be a possible factor reducing the salutary effects of bivalirudin over heparin that requires further study in future randomized investigations. The reduction in transfusions with bivalirudin was not surprising and consistent with previous reports. However, in the current analysis we also observed lower rates for all in-hospital outcomes, including death and MACE suggesting improved efficacy over UFH. What are the possible explanations for the improved efficacy with bivalirudin? First, we should consider that patients suffering a bleeding complication are at high risk of death and recurrent ischemic events. It is therefore possible that the observed reductions in mortality and MACE are related to the reductions in bleeding. 26, 27 Second, the improved ischemic protection observed in our analysis may also be explained by the more predictable and potent thrombin inhibition afforded by bivalirudin that may be especially relevant in PVI where a high thrombus burden is frequently present. Similar observations of lower mortality irrespective of bleeding have been previously reported in high-risk ST-segmentelevation myocardial infarction patients undergoing primary PCI. 28 Finally, the association between bivalirudin and fewer amputations is a new and interesting observation with obvious important clinical ramifications and will require further investigation.
There are several limitations of this analysis. First, this study used hospital database elements, which may be less robust than those captured prospectively in randomized trials. However, with a lack of large, controlled clinical trials assessing the impact of anticoagulant therapy in PVI, this observational study provides a better understanding of intervention strategies and enabled the clinical benefits to be quantified. Second, missing medication records in electronic medical databases are often inevitable and particularly prevalent when hospitals might have no incentive to record medications with a low-acquisition cost, such as UFH. In this study, a significant number (24%) of patients undergoing PVI with no record of anticoagulation (either bivalirudin or UFH) were excluded from the analyses, which may limit the generalizability of our findings. In addition, with the exception of bleeding, which can be inferred from transfusion requirements, an observational, database study such as the present one does not systematically collect procedural complications. Such an analysis will be part of the soon to be reported, randomized Endovascular Interventions With Angiomax (ENDOMAX) trial. Third, the Premier database does not use time stamping, so assumptions were made about the procedural anticoagulant based on whichever anticoagulant was administered on the day of the procedure. In addition, given the fact that bivalirudin was used disproportionately by cardiologists, PSM removed a large number of severely symptomatic patients from the matching cohort. Although our sensitivity analyses largely confirmed the PSM-derived results, the generalizability of these data to the most critically ill patients with peripheral vascular disease will probably require confirmation from a randomized clinical trial. Finally, despite PSM, residual bias and confounding from unmeasured variables may have influenced our findings.
Conclusions
This analysis from a large US hospital database has documented that when compared with UFH, bivalirudin therapy is associated with significant reductions in important clinical end points in patients undergoing PVI. The effects associated with bivalirudin treatment were robust and consistent across clinically relevant subgroups. These findings await corroboration in an ongoing randomized clinical trial.
